Molecular inhibitors targeting BCR-dependent ABC DLBCLs include: entospletinib and fostamatinib for spleen tyrosine kinase (SYK); ibrutinib, zanubrutinib, ARQ-531, LOXO-305, DTRMWXHS-12, and acalabrutinib for BTK; enzastaurin for protein kinase Cβ (PKCβ) (Fig. 4). The gene discussed is BCR; the disease is aneurysmal bone cyst.